Empagliflozin
(Synonyms: 恩格列净; BI 10773) 目录号 : GC16212
Empagliflozin (BI 10773)是一种强效、竞争性、选择性的钠-葡萄糖共转运蛋白2（SGLT-2）抑制剂，对人源SGLT-2的IC50值为3.1nM。
Cas No.:864070-44-0
Sample solution is provided at 25 µL, 10mM.
Empagliflozin (BI 10773) is a potent, competitive, and selective inhibitor of the sodium glucose transporter 2 (SGLT-2) with an IC50 of 3.1nM for hSGLT-2[1]. Empagliflozin can lower blood glucose levels by blocking SGLT2 cotransport protein in the proximal renal gyral tubule, promoting urinary glucose excretion, and preventing glucose reabsorption[2]. Empagliflozin is widely used in the treatment of type 2 diabetes, heart failure, chronic kidney and cancer[3].
Empagliflozin treatment for 72h can reduce high glucose induced TLR4 expression, NF-κB binding, IL-6 secretion, AP-1 binding and CIV expression in HK2 cells[4]. Empaglifozin (50µM, 24h) restored heparinase III-mediated glycocalyx (GCX) disruption and the normal mechanotransduction responses in GCX-compromised Human abdominal aortic endothelial cells (HAAECs)[5].
Empagliflozin (30mg/kg) supplementation protects mice from diet-induced weight gain, hyperglycaemic, hyperinsulinaemic and insulin resistant[6]. Long-term treatment with Empagliflozin (3mg/kg; 5 weeks) improves glycaemic control and features of metabolic syndrome in Zucker diabetic fatty rats[7].
References:
[1]. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012 Jan;14(1):83-90. doi: 10.1111/j.1463-1326.2011.01517.x. Epub 2011 Nov 13. PMID: 21985634.
[2]. Mascolo A, Di Napoli R, Balzano N, et al. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Front Cardiovasc Med. 2022 Sep 21;9:1010693. doi: 10.3389/fcvm.2022.1010693. PMID: 36211584; PMCID: PMC9532622.
[3]. Wu W, Wang Y, Xie J, et al. Empagliflozin: a potential anticancer drug. Discov Oncol. 2023 Jul 12;14(1):127. doi: 10.1007/s12672-023-00719-x. PMID: 37436535; PMCID: PMC10338413. [4]. Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy? PLoS One. 2013;8(2):e54442. doi: 10.1371/journal.pone.0054442. Epub 2013 Feb 4. PMID: 23390498; PMCID: PMC3563635.
[5]. Cooper S, Teoh H, Campeau MA, et al. Empagliflozin restores the integrity of the endothelial glycocalyx in vitro. Mol Cell Biochem. 2019 Sep;459(1-2):121-130. doi: 10.1007/s11010-019-03555-2. Epub 2019 May 24. PMID: 31127491.
[6]. Radlinger B, Ress C, Folie S, et al. Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis. Diabetologia. 2023 Apr;66(4):754-767. doi: 10.1007/s00125-022-05851-x. Epub 2022 Dec 16. PMID: 36525084; PMCID: PMC9947060.
[7]. Thomas L, Grempler R, Eckhardt M, et al. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab. 2012 Jan;14(1):94-6. doi: 10.1111/j.1463-1326.2011.01518.x. Epub 2011 Nov 13. PMID: 21985693.
Empagliflozin (BI 10773)是一种强效、竞争性、选择性的钠-葡萄糖共转运蛋白2（SGLT-2）抑制剂，对人源SGLT-2的IC50值为3.1nM[1]。Empagliflozin可以通过抑制肾脏近曲小管中的SGLT-2共转运蛋白，促进尿糖排泄，阻止葡萄糖重吸收，从而有效降低血糖水平[2]。Empagliflozin广泛应用于2型糖尿病、心力衰竭、慢性肾病及癌症的治疗研究[3]。
在HK2细胞中，Empagliflozin处理72小时可显著降低高糖诱导的TLR4表达、NF-κB结合、IL-6分泌、AP-1结合及CIV表达[4]。Empagliflozin（50µM，24小时）能够修复肝素酶III介导的糖萼（GCX）损伤，并恢复人腹主动脉内皮细胞（HAAECs）中糖萼受损后的正常机械传导反应[5]。
在小鼠模型中，Empagliflozin（30mg/kg）能够有效预防饮食诱导的体重增加、高血糖、高胰岛素血症及胰岛素抵抗[6]。长期使用Empagliflozin（3mg/kg，5周）可改善Zucker糖尿病肥胖大鼠的血糖控制及代谢综合征特征[7]。
| Cell experiment [1]: | |
Cell lines | HK2 cells |
Preparation Method | HK2 cells were exposed to 30mM D-glucose plus 500nM Empagliflozin for up to 72h. Then cells were harvested for Western Blot analysis to detect the protein levels of TLR4. |
Reaction Conditions | 500nM; 72h |
Applications | Empagliflozin treatment significantly inhibited high glucose induced TLR4 expression. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | 6-week-old C57BL/6 mice were fed four different diets: standard control diet (CD); CD with added Empagliflozin (CDE); western-type diet (WD) and WD with added Empagliflozin (WDE). Diets were fed to the mice for 10 weeks, with weekly measurements of capillary blood glucose via tail vein puncture and a handheld glucometer and weekly measurements of body weight and water and food consumption. |
Dosage form | 30mg/kg; 10 weeks; oral. |
Applications | Empagliflozin treatment prevents diet-induced obesity, hyperglycaemia and hyperinsulinaemia. |
References: | |
| Cas No. | 864070-44-0 | SDF | |
| 别名 | 恩格列净; BI 10773 | ||
| 化学名 | (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol | ||
| Canonical SMILES | C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl | ||
| 分子式 | C23H27ClO7 | 分子量 | 450.91 |
| 溶解度 | ≥ 20.75mg/mL in DMSO, ≥ 7.06 mg/mL in EtOH with ultrasonic | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2177 mL | 11.0887 mL | 22.1774 mL |
| 5 mM | 0.4435 mL | 2.2177 mL | 4.4355 mL |
| 10 mM | 0.2218 mL | 1.1089 mL | 2.2177 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
